SlideShare uma empresa Scribd logo
1 de 28
Baixar para ler offline
December 2011
Pharmacovigilance
Are you concerned enough?
What is Pharmacovigilance (PV)?
The science and activities relating to the detection, assessment,
understanding and prevention of adverse effects or any other
medicine-related problem
– World Health Organization
Pharmaco - Vigilance
 Pharmaco = medicine
 Vigilare = to watch
 alert watchfulness
 wakefulness
 watchfulness in respect of danger; care; caution; circumspection
 the process of paying close and continuous attention
Definition
 Adverse Drug Reaction
 "A response to a drug which is noxious and unintended, and which occurs at
doses normally used in man for the prophylaxis, diagnosis, or therapy of disease,
or for the modification of physiological function."
 Adverse Event
 Any untoward medical occurrence that may present during treatment with a
pharmaceutical product but which does not necessarily have a causal relationship
with this treatment
 Side Effect
 Any unintended effect of a pharmaceutical product occurring at doses normally
used in man which is related to the pharmacological properties of the drug
The Aims of Pharmacovigilance
 To improve patient care and safety
 To improve public health and safety
 To contribute to the assessment of benefit, harm,
effectiveness and risk of medicines
 To promote understanding, education and clinical training
What to Report?
SERIOUS ADRS
 A serious adverse event (experience) or reaction is any
untoward medical occurrence that at any dose:
 results in death,
 is life-threatening,
 requires inpatient hospitalization of prolongation of existing
hospitalization,
 is a congenital anomaly/birth defect.
NOTE: The term “life-threatening” in the definition of “serious” refers to an event
in which the patient was at risk of death at the time of the event; it does not
refer to an event which hypothetically might have caused death if it was more
severe.
Adverse Reactions:Possible Causes
 Intrinsic factors of the drug
 Pharmacological
 Idiosyncratic
 Carcinogenicity, Mutagenicity
 Teratogenicity
 Extrinsic factors
 Adulterants
 Contamination
 Underlying medical conditions
 Interactions
 Wrong usage
What Should be Reported
 New drugs
 Report all suspected reactions including minor ones
 For established or well known drugs
 All serious, unexpected, unusual ADRs
 Change in frequency of a given reaction
 ADRs to generics not seen with innovator products
 ADRs to traditional medicines
What Should be Reported
 All suspected drug-drug, drug-food, drug-food supplement
interactions
 Statement highlighting marine source of supplements such
as glucosamine so that can be avoided by those with allergy
to sea food
 ADRs associated with drug withdrawals
 ADRs due to medication errors
 eg vincristine given IT
 ADRs due to lack of efficacy or suspected pharmaceutical
defects
Why ADRs are important ?
 5% of hospital admissions
 Death of 1 in 1000 medical inpatients
 Complicates drug therapy
 Decrease compliance
Why ADRs are important ?
30 – 50% of all ADRs are preventable
Why do we need
pharmacovigilance?
Why do we need
pharmacovigilance?
Reason 1:
 Humanitarian concern –
 Insufficient evidence of safety from clinical trials
 Animal experiments
 Phase 1 – 3 studies prior to marketing authorization
Why do we need
pharmacovigilance?
Reason 2
 Medicines are supposed to save lives
 Dying from a disease is sometimes unavoidable; dying from a
medicine is unacceptable.
WHO. Geneva 2005
Why do we need
pharmacovigilance?
Reason 3: ADRs are expensive !!
 6.5% of admissions are due to ADRs
 Seven 800-bed hospitals are occupied by ADR patients
Cost of ADRs ?
 ADR related cost to the country exceeds the cost of the
medications themselves
Why do we need
pharmacovigilance?
Reason 4:
 Promoting rational use of medicines and adherence
Pharmacovigilance system
 Records medication related errors
 Analyses those errors
 Implements interventions
 Promotes patient safety
 Prevent 'preventable errors'
Actionable learning system
ARGUS – ARIS Global – Phase Forward (Empirica)
Passive - Proactive
Future Pro-Active State
Risk
Management
Aggregate
Reporting
Signal Detection
Adverse Case
Management
Passive - Proactive
Current Passive State
Risk
Management
Signal Detection
Aggregate
Reporting
What can we do?
What can we do?
 Develop procedures for the identification, reporting and
follow up of adverse drug events
What can we do?
 Assess the current technology used in the drug safety process
and assist in implementation of new systems
What can we do?
 Evaluate data quality and data integrity controls in place
What can we do?
 Prepare risk minimization action plan (RiskMAP)
What can we do?
 Assess current drug safety and pharmacovigilance training
programs
What can we do?
 Reconcile internal processes for recording safety data received
from multiple sources
For more information:
Monica Dema, Manager New
Business Development
973.658.3133
Or
Monica.Dema@RCMT.com
Or
@MonicaDema

Mais conteúdo relacionado

Semelhante a pharmacovigilance-111031093044-phpapp01.pdf

An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,MizoramAn overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizorampougang golmei
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug ReactionNishu Vora
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug ReactionNishu Vora
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug ReactionNishu Vora
 
Understanding pharmacovigilance
Understanding pharmacovigilanceUnderstanding pharmacovigilance
Understanding pharmacovigilancefinenessinstitute
 
Adverse Drug Reactions.pptx
Adverse Drug Reactions.pptxAdverse Drug Reactions.pptx
Adverse Drug Reactions.pptxAjithJs2
 
Spontaneous Reporting and Prescription Event Monitoring.pptx
Spontaneous Reporting and Prescription Event Monitoring.pptxSpontaneous Reporting and Prescription Event Monitoring.pptx
Spontaneous Reporting and Prescription Event Monitoring.pptxDrRajeshHadia
 
Pharmacovigilance STUDY
Pharmacovigilance STUDYPharmacovigilance STUDY
Pharmacovigilance STUDYSuvarta Maru
 
Pharmacovigilance - an overview
Pharmacovigilance - an overview Pharmacovigilance - an overview
Pharmacovigilance - an overview S S Shiva
 
Pharmacovigilance AN
Pharmacovigilance ANPharmacovigilance AN
Pharmacovigilance ANAhmed Nouri
 
Ashutosh pharmacovigilance
Ashutosh pharmacovigilance Ashutosh pharmacovigilance
Ashutosh pharmacovigilance ASHUTOSH MISHRA
 
Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Shaukat Patel MS R.Ph.
 
Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Shaukat Patel MS R.Ph.
 

Semelhante a pharmacovigilance-111031093044-phpapp01.pdf (20)

An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,MizoramAn overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug Reaction
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug Reaction
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug Reaction
 
Understanding pharmacovigilance
Understanding pharmacovigilanceUnderstanding pharmacovigilance
Understanding pharmacovigilance
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Basics Of Pharmacovigilance
Basics Of PharmacovigilanceBasics Of Pharmacovigilance
Basics Of Pharmacovigilance
 
Adverse Drug Reactions.pptx
Adverse Drug Reactions.pptxAdverse Drug Reactions.pptx
Adverse Drug Reactions.pptx
 
Spontaneous Reporting and Prescription Event Monitoring.pptx
Spontaneous Reporting and Prescription Event Monitoring.pptxSpontaneous Reporting and Prescription Event Monitoring.pptx
Spontaneous Reporting and Prescription Event Monitoring.pptx
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Pharmacovigilance STUDY
Pharmacovigilance STUDYPharmacovigilance STUDY
Pharmacovigilance STUDY
 
Pharmacovigilance System
Pharmacovigilance SystemPharmacovigilance System
Pharmacovigilance System
 
Pharmacovigilance - an overview
Pharmacovigilance - an overview Pharmacovigilance - an overview
Pharmacovigilance - an overview
 
Pv overview (2)
Pv overview (2)Pv overview (2)
Pv overview (2)
 
Pharmacovigilance AN
Pharmacovigilance ANPharmacovigilance AN
Pharmacovigilance AN
 
Ashutosh pharmacovigilance
Ashutosh pharmacovigilance Ashutosh pharmacovigilance
Ashutosh pharmacovigilance
 
Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)
 
Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)
 
Introduction to Pharmacovigilance.pptx
Introduction to Pharmacovigilance.pptxIntroduction to Pharmacovigilance.pptx
Introduction to Pharmacovigilance.pptx
 
Pharmacovigilence
PharmacovigilencePharmacovigilence
Pharmacovigilence
 

Mais de dabloosaha

Institutional review board or Independent ethics committee.pdf
Institutional review board or Independent ethics committee.pdfInstitutional review board or Independent ethics committee.pdf
Institutional review board or Independent ethics committee.pdfdabloosaha
 
signaldetectionandmanagement-210803014643.pdf
signaldetectionandmanagement-210803014643.pdfsignaldetectionandmanagement-210803014643.pdf
signaldetectionandmanagement-210803014643.pdfdabloosaha
 
lecture05_causality-methods_2018_lareb_who-6-kl.pptx
lecture05_causality-methods_2018_lareb_who-6-kl.pptxlecture05_causality-methods_2018_lareb_who-6-kl.pptx
lecture05_causality-methods_2018_lareb_who-6-kl.pptxdabloosaha
 
guidelines-150703103126-lva1-app6891.pdf
guidelines-150703103126-lva1-app6891.pdfguidelines-150703103126-lva1-app6891.pdf
guidelines-150703103126-lva1-app6891.pdfdabloosaha
 
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdfdabloosaha
 
pv-signalandsignaldetection-210915063241.pdf
pv-signalandsignaldetection-210915063241.pdfpv-signalandsignaldetection-210915063241.pdf
pv-signalandsignaldetection-210915063241.pdfdabloosaha
 
aggregatereportingpvkatalysthls-170327013344.pdf
aggregatereportingpvkatalysthls-170327013344.pdfaggregatereportingpvkatalysthls-170327013344.pdf
aggregatereportingpvkatalysthls-170327013344.pdfdabloosaha
 
icsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdficsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdfdabloosaha
 
STUDY DESIGNS IN CLINICAL TRIALS.pdf
STUDY DESIGNS IN CLINICAL TRIALS.pdfSTUDY DESIGNS IN CLINICAL TRIALS.pdf
STUDY DESIGNS IN CLINICAL TRIALS.pdfdabloosaha
 

Mais de dabloosaha (9)

Institutional review board or Independent ethics committee.pdf
Institutional review board or Independent ethics committee.pdfInstitutional review board or Independent ethics committee.pdf
Institutional review board or Independent ethics committee.pdf
 
signaldetectionandmanagement-210803014643.pdf
signaldetectionandmanagement-210803014643.pdfsignaldetectionandmanagement-210803014643.pdf
signaldetectionandmanagement-210803014643.pdf
 
lecture05_causality-methods_2018_lareb_who-6-kl.pptx
lecture05_causality-methods_2018_lareb_who-6-kl.pptxlecture05_causality-methods_2018_lareb_who-6-kl.pptx
lecture05_causality-methods_2018_lareb_who-6-kl.pptx
 
guidelines-150703103126-lva1-app6891.pdf
guidelines-150703103126-lva1-app6891.pdfguidelines-150703103126-lva1-app6891.pdf
guidelines-150703103126-lva1-app6891.pdf
 
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf
 
pv-signalandsignaldetection-210915063241.pdf
pv-signalandsignaldetection-210915063241.pdfpv-signalandsignaldetection-210915063241.pdf
pv-signalandsignaldetection-210915063241.pdf
 
aggregatereportingpvkatalysthls-170327013344.pdf
aggregatereportingpvkatalysthls-170327013344.pdfaggregatereportingpvkatalysthls-170327013344.pdf
aggregatereportingpvkatalysthls-170327013344.pdf
 
icsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdficsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdf
 
STUDY DESIGNS IN CLINICAL TRIALS.pdf
STUDY DESIGNS IN CLINICAL TRIALS.pdfSTUDY DESIGNS IN CLINICAL TRIALS.pdf
STUDY DESIGNS IN CLINICAL TRIALS.pdf
 

Último

1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdfQucHHunhnh
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpinRaunakKeshri1
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxheathfieldcps1
 
Russian Call Girls in Andheri Airport Mumbai WhatsApp 9167673311 💞 Full Nigh...
Russian Call Girls in Andheri Airport Mumbai WhatsApp  9167673311 💞 Full Nigh...Russian Call Girls in Andheri Airport Mumbai WhatsApp  9167673311 💞 Full Nigh...
Russian Call Girls in Andheri Airport Mumbai WhatsApp 9167673311 💞 Full Nigh...Pooja Nehwal
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104misteraugie
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Celine George
 
social pharmacy d-pharm 1st year by Pragati K. Mahajan
social pharmacy d-pharm 1st year by Pragati K. Mahajansocial pharmacy d-pharm 1st year by Pragati K. Mahajan
social pharmacy d-pharm 1st year by Pragati K. Mahajanpragatimahajan3
 
APM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAPM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAssociation for Project Management
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptxVS Mahajan Coaching Centre
 
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...fonyou31
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...EduSkills OECD
 
Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Disha Kariya
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxSayali Powar
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactPECB
 
Separation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesSeparation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesFatimaKhan178732
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactdawncurless
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxiammrhaywood
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfsanyamsingh5019
 

Último (20)

Advance Mobile Application Development class 07
Advance Mobile Application Development class 07Advance Mobile Application Development class 07
Advance Mobile Application Development class 07
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpin
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1
 
Russian Call Girls in Andheri Airport Mumbai WhatsApp 9167673311 💞 Full Nigh...
Russian Call Girls in Andheri Airport Mumbai WhatsApp  9167673311 💞 Full Nigh...Russian Call Girls in Andheri Airport Mumbai WhatsApp  9167673311 💞 Full Nigh...
Russian Call Girls in Andheri Airport Mumbai WhatsApp 9167673311 💞 Full Nigh...
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17
 
social pharmacy d-pharm 1st year by Pragati K. Mahajan
social pharmacy d-pharm 1st year by Pragati K. Mahajansocial pharmacy d-pharm 1st year by Pragati K. Mahajan
social pharmacy d-pharm 1st year by Pragati K. Mahajan
 
APM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAPM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across Sectors
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
 
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 
Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
Separation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesSeparation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and Actinides
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdf
 

pharmacovigilance-111031093044-phpapp01.pdf

  • 2. What is Pharmacovigilance (PV)? The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem – World Health Organization
  • 3. Pharmaco - Vigilance  Pharmaco = medicine  Vigilare = to watch  alert watchfulness  wakefulness  watchfulness in respect of danger; care; caution; circumspection  the process of paying close and continuous attention
  • 4. Definition  Adverse Drug Reaction  "A response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function."  Adverse Event  Any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment  Side Effect  Any unintended effect of a pharmaceutical product occurring at doses normally used in man which is related to the pharmacological properties of the drug
  • 5. The Aims of Pharmacovigilance  To improve patient care and safety  To improve public health and safety  To contribute to the assessment of benefit, harm, effectiveness and risk of medicines  To promote understanding, education and clinical training
  • 6. What to Report? SERIOUS ADRS  A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose:  results in death,  is life-threatening,  requires inpatient hospitalization of prolongation of existing hospitalization,  is a congenital anomaly/birth defect. NOTE: The term “life-threatening” in the definition of “serious” refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe.
  • 7. Adverse Reactions:Possible Causes  Intrinsic factors of the drug  Pharmacological  Idiosyncratic  Carcinogenicity, Mutagenicity  Teratogenicity  Extrinsic factors  Adulterants  Contamination  Underlying medical conditions  Interactions  Wrong usage
  • 8. What Should be Reported  New drugs  Report all suspected reactions including minor ones  For established or well known drugs  All serious, unexpected, unusual ADRs  Change in frequency of a given reaction  ADRs to generics not seen with innovator products  ADRs to traditional medicines
  • 9. What Should be Reported  All suspected drug-drug, drug-food, drug-food supplement interactions  Statement highlighting marine source of supplements such as glucosamine so that can be avoided by those with allergy to sea food  ADRs associated with drug withdrawals  ADRs due to medication errors  eg vincristine given IT  ADRs due to lack of efficacy or suspected pharmaceutical defects
  • 10. Why ADRs are important ?  5% of hospital admissions  Death of 1 in 1000 medical inpatients  Complicates drug therapy  Decrease compliance
  • 11. Why ADRs are important ? 30 – 50% of all ADRs are preventable
  • 12. Why do we need pharmacovigilance?
  • 13. Why do we need pharmacovigilance? Reason 1:  Humanitarian concern –  Insufficient evidence of safety from clinical trials  Animal experiments  Phase 1 – 3 studies prior to marketing authorization
  • 14. Why do we need pharmacovigilance? Reason 2  Medicines are supposed to save lives  Dying from a disease is sometimes unavoidable; dying from a medicine is unacceptable. WHO. Geneva 2005
  • 15. Why do we need pharmacovigilance? Reason 3: ADRs are expensive !!  6.5% of admissions are due to ADRs  Seven 800-bed hospitals are occupied by ADR patients
  • 16. Cost of ADRs ?  ADR related cost to the country exceeds the cost of the medications themselves
  • 17. Why do we need pharmacovigilance? Reason 4:  Promoting rational use of medicines and adherence
  • 18. Pharmacovigilance system  Records medication related errors  Analyses those errors  Implements interventions  Promotes patient safety  Prevent 'preventable errors' Actionable learning system ARGUS – ARIS Global – Phase Forward (Empirica)
  • 19. Passive - Proactive Future Pro-Active State Risk Management Aggregate Reporting Signal Detection Adverse Case Management
  • 20. Passive - Proactive Current Passive State Risk Management Signal Detection Aggregate Reporting
  • 21. What can we do?
  • 22. What can we do?  Develop procedures for the identification, reporting and follow up of adverse drug events
  • 23. What can we do?  Assess the current technology used in the drug safety process and assist in implementation of new systems
  • 24. What can we do?  Evaluate data quality and data integrity controls in place
  • 25. What can we do?  Prepare risk minimization action plan (RiskMAP)
  • 26. What can we do?  Assess current drug safety and pharmacovigilance training programs
  • 27. What can we do?  Reconcile internal processes for recording safety data received from multiple sources
  • 28. For more information: Monica Dema, Manager New Business Development 973.658.3133 Or Monica.Dema@RCMT.com Or @MonicaDema